文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis.

作者信息

Gu Xiao-Bin, Tian Tian, Tian Xiao-Jing, Zhang Xiao-Jun

机构信息

Cancer Center, Chinese PLA General Hospital and Chinese PLA Medical School, Beijing, China.

Nanlou Department of Respiratory Disease, Chinese PLA General Hospital and Chinese PLA Medical School, Beijing, China.

出版信息

Sci Rep. 2015 Jul 24;5:12493. doi: 10.1038/srep12493.


DOI:10.1038/srep12493
PMID:26205001
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4513342/
Abstract

Published data on the prognostic significance of neutrophil-to-lymphocyte ratio (NLR) in non-small cell lung cancer (NSCLC) are controversial. We performed a meta-analysis to more accurately assess its prognostic value. The analysis was performed based on the data from 14 studies with 3,656 patients to estimate the correlation between NLR and overall survival (OS) and progression-free survival (PFS) in NSCLC. Hazard ratio (HR) with 95% confidence interval (CI) were calculated to estimate the effect. We also conducted subgroup analysis and meta-regression analysis. The results demonstrated that elevated pretreatment NLR predicted poorer OS (HR: 1.70, 95% CI: 1.39-2.09) and PFS (HR: 1.63, 95% CI: 1.27-2.09) in patients with NSCLC. Subgroup analysis indicated that cut-off value of 5 showed consistently prognostic value. There was no significant heterogeneity or publication bias for OS and PFS for included studies. This meta-analysis revealed that elevated pretreatment NLR might be a predicative factor of poor prognosis for NSCLC patients.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/eb5c52d91526/srep12493-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/931ed63fb959/srep12493-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/36b3344e6411/srep12493-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/cb23a9881c7e/srep12493-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/046b3507fd2a/srep12493-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/eb5c52d91526/srep12493-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/931ed63fb959/srep12493-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/36b3344e6411/srep12493-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/cb23a9881c7e/srep12493-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/046b3507fd2a/srep12493-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8c/4513342/eb5c52d91526/srep12493-f5.jpg

相似文献

[1]
Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis.

Sci Rep. 2015-7-24

[2]
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Lung Cancer. 2017-9

[3]
Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.

Int Immunopharmacol. 2020-8

[4]
Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer.

Am J Surg. 2015-9

[5]
Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.

Oncol Res Treat. 2018-11-13

[6]
Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients.

Sci Rep. 2016-3-30

[7]
Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients.

Int J Cancer. 2016-7-1

[8]
Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies.

Cancer Treat Rev. 2017-5-29

[9]
[Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].

Zhonghua Zhong Liu Za Zhi. 2018-6-23

[10]
Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.

Clin Transl Oncol. 2020-12

引用本文的文献

[1]
Neutrophil-Related Genes Predict Prognosis and Contribute to Immunosuppression in Acute Myeloid Leukemia.

Blood Lymphat Cancer. 2025-8-18

[2]
The value of prognostic immune-inflammatory-nutritional score in predicting survival after surgery in stage I-III non-small cell lung cancer.

J Thorac Dis. 2025-6-30

[3]
T cell receptor profiling of blood to detect lung cancer.

Cancer Immunol Res. 2025-7-1

[4]
Increased Pre-Operative Lung Immune Prognostic Index Score Is a Prognostic Factor in Cases of Pathological T3 Renal Cell Carcinoma.

Curr Oncol. 2025-6-7

[5]
Single-Cell Transcriptomic Profiling Reveals KRAS/TP53-Driven Neutrophil Reprogramming in Luad: A Multi-Gene Prognostic Model and Therapeutic Targeting of RHOV.

Oncol Res. 2025-5-29

[6]
Neutrophil-to-lymphocyte ratio as a prognostic marker for lung cancer in combined pulmonary fibrosis and emphysema patients.

Eur J Med Res. 2025-4-22

[7]
Peripheral blood markers predict prognosis and irAEs of stage IV driver gene-negative lung adenocarcinoma treated with ICIs.

Front Immunol. 2025-3-28

[8]
SYSTEMIC INFLAMMATORY MARKERS - PROGNOSTIC VALUE IN OVARIAN CANCER.

Acta Endocrinol (Buchar). 2024

[9]
Postoperative short-term prognostic factors in patients with primary lung cancer who undergo lobectomy: a study on the prognostic predictors of early postoperative recurrence.

J Thorac Dis. 2024-11-30

[10]
Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer.

BMC Cancer. 2024-11-18

本文引用的文献

[1]
Prognostic significance of neutrophil-to- lymphocyte ratio in esophageal cancer: a meta-analysis.

Onco Targets Ther. 2015-4-10

[2]
Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis.

BMJ Open. 2015-4-8

[3]
Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis.

World J Gastroenterol. 2015-3-7

[4]
Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study.

Cancer Med. 2015-6

[5]
Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: a meta-analysis.

PLoS One. 2014-11-17

[6]
Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.

Asia Pac J Clin Oncol. 2017-10

[7]
Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.

J Thorac Oncol. 2015-2

[8]
Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers?

Asian Pac J Cancer Prev. 2014

[9]
The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients.

Br J Cancer. 2014-3-27

[10]
Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer.

Br J Cancer. 2014-3-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索